Overview
ImmunityBio, Inc., based in the United States, operates within the biotechnology sector, focusing on innovating immunotherapy platforms that engage the immune system's natural capabilities to fight cancer and infectious diseases. The company has been pivotal in developing therapies that address both the innate and adaptive arms of the immune system. One of the key projects of ImmunityBio includes their work on a novel cancer vaccine targeting multiple tumor types, which aims to enhance patient outcomes by inducing robust immune responses against cancer cells. Additionally, ImmunityBio has expanded its research ambit to include the development of treatments for COVID-19, aiming to create long-lasting immunity against the virus. Through these projects, ImmunityBio strives to offer transformative therapeutic options for life-threatening diseases.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for ImmunityBio, Inc. as of June 30, 2025 is 56.60 MM.
- The operating income for ImmunityBio, Inc. as of June 30, 2025 is -285.37 MM.
- The net income for ImmunityBio, Inc. as of June 30, 2025 is -367.09 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 56.60 | -285.37 | -367.09 |
| 2025-03-31 | 31.22 | -313.42 | -409.10 |
| 2024-12-31 | 14.74 | -344.18 | -413.56 |
| 2024-09-30 | 7.33 | -359.28 | -587.79 |
| 2024-06-30 | 1.31 | -359.17 | -597.65 |
| 2024-03-31 | 0.30 | -344.98 | -600.96 |
| 2023-12-31 | 0.62 | -361.36 | -583.20 |
| 2023-09-30 | 0.56 | -361.13 | -458.02 |
| 2023-06-30 | 0.59 | -371.80 | -473.38 |
| 2023-03-31 | 0.59 | -366.28 | -430.08 |
| 2022-12-31 | 0.24 | -350.67 | -416.57 |
| 2022-09-30 | 0.56 | -332.82 | -399.61 |
| 2022-06-30 | 0.51 | -320.85 | -376.30 |
| 2022-03-31 | 0.81 | -327.13 | -370.00 |
| 2021-12-31 | 0.93 | -317.42 | -346.79 |
| 2021-09-30 | 0.40 | -308.84 | -323.30 |
| 2021-06-30 | 0.48 | -285.23 | -301.28 |
| 2021-03-31 | 0.58 | -250.24 | -264.43 |
| 2020-12-31 | 0.60 | -200.67 | -221.85 |
| 2020-09-30 | 1.67 | -164.19 | -176.36 |
Income Statement: EPS
- The earnings per share basic for ImmunityBio, Inc. as of June 30, 2025 is -0.46.
- The earnings per share diluted for ImmunityBio, Inc. as of June 30, 2025 is -0.49.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -0.46 | -0.49 |
| 2025-03-31 | -0.55 | -0.58 |
| 2024-12-31 | -0.59 | -0.62 |
| 2024-09-30 | -0.86 | -0.88 |
| 2024-06-30 | -0.95 | -0.95 |
| 2024-03-31 | -1.05 | -1.06 |
| 2023-12-31 | -1.15 | -1.15 |
| 2023-09-30 | -1.04 | -1.04 |
| 2023-06-30 | -1.13 | -1.14 |
| 2023-03-31 | -1.06 | -1.05 |
| 2022-12-31 | -1.04 | -1.04 |
| 2022-09-30 | -1.00 | -1.00 |
| 2022-06-30 | -0.95 | -0.95 |
| 2022-03-31 | -0.94 | -0.94 |
| 2021-12-31 | -0.89 | |
| 2021-09-30 | -0.84 | -0.84 |
| 2021-06-30 | -0.79 | -0.79 |
| 2021-03-31 | -0.70 | -0.70 |
| 2020-12-31 | -0.59 | |
| 2020-09-30 | -0.48 | -0.48 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for ImmunityBio, Inc. as of June 30, 2025 is -349.56 MM.
- The cash from investing activities for ImmunityBio, Inc. as of June 30, 2025 is 62.85 MM.
- The cash from financing activities for ImmunityBio, Inc. as of June 30, 2025 is 294.34 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -349.56 | 62.85 | 294.34 |
| 2025-03-31 | -370.16 | 27.50 | 270.42 |
| 2024-12-31 | -391.24 | -12.25 | 281.63 |
| 2024-09-30 | -421.36 | -19.83 | 375.24 |
| 2024-06-30 | -410.00 | -100.49 | 597.16 |
| 2024-03-31 | -389.43 | -57.61 | 491.68 |
| 2023-12-31 | -366.76 | -30.47 | 558.34 |
| 2023-09-30 | -342.21 | -51.61 | 467.74 |
| 2023-06-30 | -335.41 | -37.15 | 354.23 |
| 2023-03-31 | -346.89 | 88.13 | 310.80 |
| 2022-12-31 | -337.51 | 27.30 | 233.61 |
| 2022-09-30 | -318.42 | -91.61 | 449.63 |
| 2022-06-30 | -310.54 | -79.86 | 368.30 |
| 2022-03-31 | -288.88 | -186.04 | 466.65 |
| 2021-12-31 | -274.42 | -84.89 | 505.44 |
| 2021-09-30 | -260.38 | 60.46 | 179.73 |
| 2021-06-30 | -224.66 | -6.75 | 200.29 |
| 2021-03-31 | -201.09 | -1.96 | 189.29 |
| 2020-12-31 | -171.72 | -19.81 | 150.68 |
| 2020-09-30 | -132.13 | -31.90 | 210.88 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for ImmunityBio, Inc. as of June 30, 2025 is -5.49.
- The p/book for ImmunityBio, Inc. as of June 30, 2025 is -3.80.
- The p/tbv for ImmunityBio, Inc. as of June 30, 2025 is -3.70.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -5.49 | -3.80 | -3.70 |
| 2025-03-31 | -6.48 | -5.49 | -5.32 |
| 2024-12-31 | -2.51 | -2.46 | |
| 2024-09-30 | -4.58 | -3.93 | -3.84 |
| 2024-06-30 | -7.53 | -6.55 | -6.39 |
| 2024-03-31 | -6.31 | -6.28 | -6.10 |
| 2023-12-31 | -7.29 | -8.13 | -7.78 |
| 2023-09-30 | -2.26 | -1.66 | -1.61 |
| 2023-06-30 | -2.76 | -2.23 | -2.15 |
| 2023-03-31 | -1.90 | -1.76 | |
| 2022-12-31 | -4.83 | -4.61 | |
| 2022-09-30 | -4.71 | -4.48 | |
| 2022-06-30 | -4.00 | -4.39 | -4.11 |
| 2022-03-31 | -6.44 | -9.15 | -9.10 |
| 2021-12-31 | -10.45 | -12.68 | -12.54 |
| 2021-09-30 | -18.29 | -24.05 | -23.74 |
| 2021-06-30 | |||
| 2021-03-31 | -9.35 | -8.66 | -8.59 |
| 2020-12-31 | |||
| 2020-09-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for ImmunityBio, Inc. as of June 30, 2025 is -0.14.
- The ebit (3y)/ev for ImmunityBio, Inc. as of June 30, 2025 is -0.17.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.14 | -0.17 |
| 2025-03-31 | -0.13 | -0.15 |
| 2024-12-31 | -0.22 | -0.19 |
| 2024-09-30 | -0.17 | -0.14 |
| 2024-06-30 | -0.11 | -0.09 |
| 2024-03-31 | -0.14 | -0.11 |
| 2023-12-31 | -0.12 | -0.09 |
| 2023-09-30 | -0.26 | -0.20 |
| 2023-06-30 | -0.24 | -0.19 |
| 2023-03-31 | -0.31 | -0.26 |
| 2022-12-31 | -0.14 | -0.09 |
| 2022-09-30 | -0.15 | -0.10 |
| 2022-06-30 | -0.18 | -0.12 |
| 2022-03-31 | -0.13 | -0.09 |
| 2021-12-31 | -0.09 | -0.06 |
| 2021-09-30 | -0.05 | -0.03 |
| 2021-06-30 | ||
| 2021-03-31 | -0.09 | -0.08 |
| 2020-12-31 | ||
| 2020-09-30 |
Management Effectiveness
- The roa for ImmunityBio, Inc. as of June 30, 2025 is -0.92.
- The roic for ImmunityBio, Inc. as of June 30, 2025 is -1.75.
- The croic for ImmunityBio, Inc. as of June 30, 2025 is -0.31.
- The ocroic for ImmunityBio, Inc. as of June 30, 2025 is -1.59.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.92 | -1.75 | -0.31 | -1.59 | |
| 2025-03-31 | -1.03 | -1.37 | -0.40 | -1.30 | |
| 2024-12-31 | -1.17 | -2.14 | -0.24 | -1.53 | |
| 2024-09-30 | -1.38 | -1.98 | 0.29 | -1.36 | |
| 2024-06-30 | -1.75 | -2.94 | 0.22 | -1.90 | |
| 2024-03-31 | -1.61 | -1.96 | 0.54 | -1.23 | |
| 2023-12-31 | -1.30 | -1.48 | 0.24 | -1.11 | |
| 2023-09-30 | -1.49 | -2.72 | -0.11 | -1.93 | |
| 2023-06-30 | -1.35 | -3.85 | -0.15 | -2.73 | |
| 2023-03-31 | -1.07 | -2.24 | 0.27 | -1.81 | |
| 2022-12-31 | -1.86 | -0.68 | 0.07 | -0.54 | |
| 2022-09-30 | -1.75 | -1.70 | 0.17 | -1.36 | |
| 2022-06-30 | -1.50 | -1.57 | -0.09 | -1.30 | |
| 2022-03-31 | -1.66 | -1.20 | -0.03 | -0.94 | |
| 2021-12-31 | -2.90 | -3.35 | 1.41 | -1.20 | |
| 2021-09-30 | -1.97 | -1.55 | -0.11 | -0.86 | |
| 2021-06-30 | -1.69 | -1.20 | -0.16 | -0.87 | |
| 2021-03-31 | -1.39 | -1.97 | -0.10 | -0.94 | |
| 2020-12-31 | -0.65 | -0.77 | -7.47 | -1.38 | -3.27 |
| 2020-09-30 | -1.85 | 0.75 | -1.39 |
Gross Margins
- The gross margin for ImmunityBio, Inc. as of June 30, 2025 is 1.00.
- The net margin for ImmunityBio, Inc. as of June 30, 2025 is -13.10.
- The operating margin for ImmunityBio, Inc. as of June 30, 2025 is -10.04.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 1.00 | -13.10 | -10.04 |
| 2025-03-31 | 1.00 | -28.05 | -23.34 |
| 2024-12-31 | 1.00 | -80.17 | -49.00 |
| 2024-09-30 | 1.00 | -456.92 | -274.59 |
| 2024-06-30 | 1.00 | -1,989.94 | -1,142.31 |
| 2024-03-31 | 1.00 | -937.61 | -580.97 |
| 2023-12-31 | 1.00 | -823.78 | -649.52 |
| 2023-09-30 | 1.00 | -799.62 | -628.04 |
| 2023-06-30 | 1.00 | -799.62 | -628.04 |
| 2023-03-31 | 1.00 | -733.93 | -625.04 |
| 2022-12-31 | 1.00 | -717.43 | -596.26 |
| 2022-09-30 | 1.00 | -717.43 | -596.26 |
| 2022-06-30 | 1.00 | -745.15 | -635.34 |
| 2022-03-31 | 1.00 | -457.36 | -404.37 |
| 2021-12-31 | 1.00 | -371.30 | -339.85 |
| 2021-09-30 | 1.00 | -155.00 | -143.18 |
| 2021-06-30 | 1.00 | -132.61 | -120.41 |
| 2021-03-31 | 1.00 | -456.70 | -266.66 |
| 2020-12-31 | -366.70 | -331.69 | |
| 2020-09-30 | 1.00 | -42.19 | -37.75 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1326110 |
